SCHEMBL942690

SCHEMBL942690

CC(=O)N(c1cccc(C(F)(F)F)c1)C(C(=O)NCC(=O)O)C(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR139 Q6DWJ6 1/20 0.42
NPSR1 Q6W5P4 2/20 0.41
CTSL P07711 1/20 0.40
ALDH1A1 P00352 2/20 0.39
POLB P06746 2/20 0.39
HTT P42858 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
CCR2 P41597 2/20 0.38
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2C9 P11712 2/20 0.38
HDAC6 Q9UBN7 1/20 0.38
TAS1R3 Q7RTX0 1/20 0.37
TAS1R1 Q7RTX1 1/20 0.37
KDM4E B2RXH2 1/20 0.37
PTGIR P43119 1/20 0.37
TP53 P04637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1170578 1.00 GPR139 (0.42) GPR139NPSR1CTSLALDH1A1POLB
SCHEMBL29600045 1.00 GPR139 (0.42) GPR139NPSR1CTSLALDH1A1POLB
SCHEMBL5797164 0.91 MEN1 (0.41) GPR139ALDH1A1HTTMEN1KMT2A
SCHEMBL18546019 0.90 NPSR1 (0.43) GPR139NPSR1CTSLALDH1A1POLB
SCHEMBL15016758 0.89 ALDH1A1 (0.43) GPR139NPSR1CTSLALDH1A1POLB
SCHEMBL5598191 0.87 NPSR1 (0.40) GPR139NPSR1ALDH1A1POLBHTT
SCHEMBL29600101 0.87 NPSR1 (0.40) GPR139NPSR1ALDH1A1POLBHTT
SCHEMBL5598193 0.87 NPSR1 (0.40) GPR139NPSR1ALDH1A1POLBHTT
SCHEMBL17848959 0.84 MME (0.37) ALDH1A1CYP3A4TP53OPRM1
SCHEMBL17848960 0.84 MME (0.37) ALDH1A1CYP3A4TP53OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 308 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220296488-A1 COMPOSITIONS COMPRISING AT LEAST ONE COMPOUND OF THE N-ACYLAMINO AMIDE FAMILY AND AT LEAST ONE ALKYL POLYGLYCOSIDE L'OREAL (FR) 2022-09-22 US claimed
EP-3986368-A1 COMPOSITIONS COMPRISING AT LEAST ONE COMPOUND OF THE N-ACYLAMINO AMIDE FAMILY AND AT LEAST ONE ALKYL POLYGLYCOSIDE L'OREAL (FR) 2022-04-27 EP claimed
CN-113939264-A Composition comprising at least one compound of the N-acylaminoamide family and at least one alkylpolyglycoside 莱雅公司 2022-01-14 CN claimed
WO-2020254645-A1 Compositions comprising at least one compound of the N-acylamino amide family and at least one alkyl polyglycoside L'OREAL (FR) 2020-12-24 WO claimed
EP-1889642-B1 Cosmetic compositions combining a C-glycoside derivative and a N-acylaminoamide derivative OREAL (FR) 2019-05-08 EP claimed
US-20130139841-A1 Method for Caring for and/or Making-up Wrinkles L'OREAL (FR) 2013-06-06 US claimed
US-7998933-B2 Process for treating the skin comprising applying to the skin at least one composition comprising at least one N-aminoacylamide L'OREAL S.A. (FR) 2011-08-16 US claimed
US-20110021438-A1 NOVEL COMPOUNDS OF THE N-ACYLAMINO-AMIDE FAMILY, COMPOSITIONS COMPRISING THEM AND USES THEREOF L'OREAL S.A. (FR) 2011-01-27 US claimed
US-7838020-B2 Cosmetic or dermatological composition comprising an association between a compound of the N-acylaminoamide family and at least one matrix metalloproteinase inhibitor L'OREAL (FR) 2010-11-23 US claimed
US-7786321-B2 Compounds of the N-acylamino amide family compositions comprising them and uses thereof L'OREAL S.A. (FR) 2010-08-31 US claimed
US-6998129-B2 Cosmetic or dermatological composition comprising an association between an elastase inhibitor compound of the N-acylaminoamide family and at least one anti-inflammatory compound L'OREAL (FR) 2006-02-14 US claimed
US-6987128-B2 Compounds of the N-acylamino amide family, compositions comprising same, and uses L'OREAL S.A. (FR) 2006-01-17 US claimed
US-20050142081-A1 Cosmetic or dermatological composition comprising an association between a compound of the N-acylaminoamide family and at least on matrix metalloproteinase inhibitor L'OREAL (FR) 2005-06-30 US claimed
US-6884425-B2 Cosmetic or dermatological composition comprising an association between a compound of the N-acylaminoamide family and at least one matrix metalloproteinase inhibitor L'OREAL (FR) 2005-04-26 US claimed
US-20040191203-A1 Cosmetic or dermatological composition comprising n-acylaminoamide derivatives L'OREAL (FR) 2004-09-30 US claimed
EP-1292608-B1 NOVEL COMPOUNDS OF THE N-ACYLAMINO-AMIDE FAMILY, COMPOSITIONS COMPRISING SAME, AND USES OREAL (FR) 2004-07-21 EP claimed
US-20030152596-A1 Cosmetic or dermatological composition comprising of a combination of an elastase inhibitor of the N-acylaminoamide family and at least one antifungal agent or at least one antibacterial agent L'OREAL (FR) 2003-08-14 US claimed
US-20030152600-A1 Novel compounds of the n-acylamino-amide-family, cpmpositions comprising same, and uses L'OREAL S.A. (FR) 2003-08-14 US claimed
US-20030072732-A1 Cosmetic or dermatological composition comprising an association between an elastase inhibitor compound of the N-acylaminoamide family and at least one anti-inflammatory compound L'OREAL (FR) 2003-04-17 US claimed
US-20030044438-A1 Cosmetic or dermatological composition comprising an association between a compound of the N-acylaminoamide family and at least one matrix metalloproteinase inhibitor L'OREAL (FR) 2003-03-06 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030044438-A1 Cosmetic or dermatological composition comprising an association between a compound of the N-acylaminoamide family and at least one matrix metalloproteinase inhibitor SERPINB1, ELANE, MMP7 GPR139 3155/4885NPSR1 3950/4885CTSL 347/4885
US-20220296488-A1 COMPOSITIONS COMPRISING AT LEAST ONE COMPOUND OF THE N-ACYLAMINO AMIDE FAMILY AND AT LEAST ONE ALKYL POLYGLYCOSIDE CUTA, KRT18, UGCG GPR139 575/4885NPSR1 3424/4885CTSL 3525/4885
US-20040191203-A1 Cosmetic or dermatological composition comprising n-acylaminoamide derivatives AADAC, ELANE, NAAA GPR139 3131/4885NPSR1 3914/4885CTSL 301/4885
US-20050142081-A1 Cosmetic or dermatological composition comprising an association between a compound of the N-acylaminoamide family and at least on matrix metalloproteinase inhibitor SERPINB1, ELANE, MMP7 GPR139 3070/4885NPSR1 4029/4885CTSL 339/4885
US-20030152596-A1 Cosmetic or dermatological composition comprising of a combination of an elastase inhibitor of the N-acylaminoamide family and at least one antifungal agent or at least one antibacterial agent ELANE, SERPINB1, AADAC GPR139 3966/4885NPSR1 3840/4885CTSL 249/4885
US-20110021438-A1 NOVEL COMPOUNDS OF THE N-ACYLAMINO-AMIDE FAMILY, COMPOSITIONS COMPRISING THEM AND USES THEREOF COL2A1, COL14A1, AADAC GPR139 2183/4885NPSR1 3538/4885CTSL 2428/4885
US-20030152600-A1 Novel compounds of the n-acylamino-amide-family, cpmpositions comprising same, and uses COL1A1, COL14A1, COL2A1 GPR139 1981/4885NPSR1 2249/4885CTSL 490/4885
US-20030072732-A1 Cosmetic or dermatological composition comprising an association between an elastase inhibitor compound of the N-acylaminoamide family and at least one anti-inflammatory compound SERPINB1, ELANE, AADAC GPR139 2376/4885NPSR1 3507/4885CTSL 287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.